Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Inhibikase Therapeutics (IKT) Net Margin (2020 - 2023)

Historic Net Margin for Inhibikase Therapeutics (IKT) over the last 4 years, with Q4 2023 value amounting to 440356600.0%.

  • Inhibikase Therapeutics' Net Margin fell 4403497803600.0% to 440356600.0% in Q4 2023 from the same period last year, while for Sep 2024 it was 2006393700.0%, marking a year-over-year decrease of 20063875218800.0%. This contributed to the annual value of 7711.98% for FY2023, which is 69741900.0% up from last year.
  • As of Q4 2023, Inhibikase Therapeutics' Net Margin stood at 440356600.0%, which was down 4403497803600.0% from 5993.38% recorded in Q3 2023.
  • Inhibikase Therapeutics' Net Margin's 5-year high stood at 187.4% during Q1 2021, with a 5-year trough of 440356600.0% in Q4 2023.
  • Its 4-year average for Net Margin is 27549285.01%, with a median of 5660.72% in 2023.
  • As far as peak fluctuations go, Inhibikase Therapeutics' Net Margin skyrocketed by 2000000000bps in 2022, and later tumbled by 2000000000bps in 2023.
  • Inhibikase Therapeutics' Net Margin (Quarter) stood at 708.85% in 2020, then crashed by -36487bps to 259342.54% in 2021, then skyrocketed by 97bps to 6819.64% in 2022, then crashed by -6457080bps to 440356600.0% in 2023.
  • Its Net Margin was 440356600.0% in Q4 2023, compared to 5993.38% in Q3 2023 and 5328.07% in Q2 2023.